Axogen Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $251.2M+34.1% YoYTTM through 30 Jun 2026
Net Income -$33.5MTTM through 30 Jun 2026
Free Cash Flow $8.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 75.2% |
| EBITDA Margin | -2.5% |
| Operating Margin | -4.6% |
| Net Margin | -13.4% |
Returns
-13.1%ROE
-11.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.60x
Net Debt-$101.6Mnet cash position
Cash & Equivalents$94.6M
Quality Metrics
Altman Z-Score32.11
Piotroski F-Score3 / 9
FCF Margin3.4%
Rule of 4014.7
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $225.2M
Diluted EPS-$0.67TTMFY2025: $-0.34
Dividend
No dividend
Capital Allocation
R&D Spend$36M
Capex Intensity2.6%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.